Skip to main content

Pulmonary hypertension

Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.

Pulmonary hypertension (PH) is an increase in mean pulmonary arterial pressure (PAP), which can be caused by or associated with a wide variety of conditions.

Idiopathic pulmonary arterial hypertension (PAH) is a rare disorder that can be defined as a sustained elevation in PAP and pulmonary vascular resistance, with normal pulmonary artery wedge pressure, in the absence of a known cause. It is a diagnosis of exclusion after other possible causes of PH have been excluded. It is a severe and often rapidly progressive illness in many cases.

The injury to the pulmonary endothelium causes a tendency to in situ thrombosis in the pulmonary arterial tree, the so-called thrombotic pulmonary arteriopathy. The disease process continues through vascular scarring, endothelial dysfunction and proliferation of smooth muscle cells within the intima and media of the pulmonary arterial tree, causing progressive pulmonary arterial hypertension. This leads to progressive right heart strain due to obliteration of small pulmonary arterial vessels, and eventually right heart failure.

Continue reading below


PH is a haemodynamic and pathophysiological condition defined as an increase in mean PAP ≥25 mm Hg at rest as assessed by right heart catheterisation.

PAH is a clinical condition characterised by the presence of precapillary PH in the absence of other causes of precapillary PH such as PH due to lung diseases, chronic thromboembolic PH, or other rare diseases (see 'Classification', below). PAH includes different forms that share a similar clinical picture and virtually identical pathological changes of the lung microcirculation.

Classification of pulmonary hypertension1

Classification is crucial in determining the treatment and prognosis2.

  • PAH:

    • Idiopathic.

    • Heritable:

      • There is a small subset (~6%) of cases that are inherited in an autosomal dominant fashion due to mutations in the BMPR2 gene (receptor in TGF-beta family)3.

      • Other mutations.

    • Drug- and toxin-induced.

    • Associated with:

      • HIV infection, portal hypertension, congenital heart disease, schistosomiasis, chronic haemolytic anaemia.

      • A relatively high rate in certain connective tissue disorders such as the CREST syndrome (Calcinosis, Raynaud's phenomenon, (O)Esophageal dysmotility, Sclerodactyly and Telangiectasia), progressive systemic sclerosis, Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus (SLE), mixed connective tissue disorder and polymyositis/dermatomyositis4.

  • Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis.

  • Persistent PH of the newborn.

  • PH due to left heart disease: systolic dysfunction, diastolic dysfunction, valvular disease, left heart inflow or outflow tract obstruction, congenital cardiomyopathies, pulmonary vein stenosis.

  • PH due to lung diseases and/or hypoxia:

    • Chronic obstructive pulmonary disease.

    • Interstitial lung disease.

    • Other pulmonary diseases with mixed restrictive and obstructive pattern.

    • Sleep-disordered breathing.

    • Alveolar hypoventilation disorders.

    • Chronic exposure to high altitude.

    • Developmental abnormalities.

  • Chronic thromboembolic pulmonary hypertension and other pulmonary artery obstructions.

  • PH with unclear and/or multifactorial mechanisms:

    • Haematological disorders: myeloproliferative disorders, splenectomy.

    • Systemic disorders: sarcoidosis, pulmonary Langerhans' cell histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, vasculitis.

    • Metabolic disorders: glycogen storage disease, Gaucher's disease, thyroid disorders.

    • Others: tumour obstruction, fibrosing mediastinitis, chronic kidney disease, segmental pulmonary hypertension.

The World Health Organization (WHO) has devised an alternative classification system5:

  • Group 1 - idiopathic.

  • Group 2 - secondary to left heart disease, valvular heart disease, restrictive cardiomyopathy.

  • Group 3 - secondary to chronic lung disease and environmental hypoxaemia.

  • Group 4 - due to chronic thrombotic disease, embolic disease, or both.

  • Group 5 - metabolic disorders, systemic disorders, haematological diseases, and other miscellaneous causes.

Continue reading below


Idiopathic PAH is rare.The prevalence of PAH is estimated at 15-50 per million. The incidences are estimated to be 1-3.3 per million per year for idiopathic PAH and 1.75-3.7 per million per year for chronic thromboembolic PH.

PH is more common in severe respiratory and cardiac disease, occurring in 18-50% of patients assessed for transplantation or lung volume reduction surgery, and in 7-83% of those with diastolic heart failure.

Between 0.5% and 4% of patients develop chronic thromboembolic PH after acute pulmonary embolism. There is an increased risk for patients presenting with large, recurrent or unprovoked clots.

A Canadian study found an increase in adult PH, largely in Group 26.


Most commonly presents with progressive breathlessness, weakness and tiredness. Exertional dizziness and syncope may also develop. Oedema and ascites tend to occur late in the disease. Angina and tachyarrythmias, particularly atrial flutter, may also occur. Haemoptysis is uncommon but may occur in Eisenmenger's syndrome and chronic thromboembolic PH.

Clinical signs include right ventricular (parasternal) heave, a loud pulmonary second heart sound, murmur of pulmonary regurgitation, systolic murmur of tricuspid regurgitation, raised jugular venous pressure, peripheral oedema and ascites. These signs may be subtle or absent in early disease.

There may also be signs of associated conditions, such as connective tissue disease or liver disease.

Continue reading below

Differential diagnosis


  • Routine biochemistry screen including LFTs (portal hypertension), TFTs and autoimmune screening - particularly antinuclear antibody to detect possible SLE/scleroderma-like syndrome.

  • CXR to exclude other lung diseases but this is not useful for diagnosing PH.

  • ECG - can show right ventricular hypertrophy and strain patterns but may be normal.

  • Pulmonary function tests.

  • Lung biopsy may be needed to exclude interstitial lung disease.

  • Polysomnography may be used to exclude obstructive sleep apnoea.

  • Echocardiography to assess right ventricular function and estimate pulmonary arterial pressures.

  • High-resolution CT of the thorax to investigate other possible causes of PH.

  • Isotope perfusion lung scanning has high sensitivity for chronic thromboembolic PH.

  • MRI:

    • MRI to assess cardiac structure and function, prognosis and response to treatment.

    • Magnetic resonance pulmonary angiography in the assessment of chronic thromboembolic PH operability.

    • Magnetic resonance perfusion imaging is as sensitive as isotope perfusion lung scanning.

  • Right heart catheterisation is needed to confirm the diagnosis by directly measuring pulmonary pressure.


Specific treatments exist for PAH and chronic thromboembolic PH. In PAH due to left heart disease, lung disease or hypoxia, treatment is best directed at the underlying condition2. Patients are best managed through regional specialist units that have the expertise to manage their severe illness, relevant complex investigations, expensive medication and clinical trial administration.

  • Management of any underlying cause.

  • Although some drugs seem to have significant effects on symptoms and exercise tolerance in the short term, the evidence available suggests they have little effect on long-term survival8.

  • Atrial septostomy is a palliative procedure that may provide some benefit to patients whose condition is deteriorating.

Cardiosupportive therapy

  • Supplemental oxygen can help symptomatically with exercise tolerance. Diuretics are used to treat right heart failure and remove peripheral oedema, along with digoxin as a positive inotrope.

  • There are no convincing trial data to support their use but consensus is that they are helpful.

  • High-dose calcium-channel blockade (eg, diltiazem titrated to 480-720 mg/day or nifedipine titrated to 60-120 mg/day) may be used for idiopathic PAH. Because of the potential negative inotropic effect, treatment should not be started without a positive acute vasoreactive test2.

Prostacyclin analogues

  • Prostacyclin is a potent vasodilator and inhibitor of platelet aggregation. Various prostacyclin analogues may be used to treat the condition. Most need to be given by continuous intravenous infusion, usually through a long-term indwelling central venous catheter.

  • A Cochrane review found clinical and statistical benefit for intravenous prostacyclin with improved functional class, 6-minute walking distance, mortality, symptoms scores, and cardiopulmonary haemodynamics. However, significant adverse events occurred. The evidence for the benefits of oral preparations is less convincing9.

Endothelin-A receptor antagonists2

  • Endothelin is a potent vasoconstrictor of vascular smooth muscle. Bosentan and ambrisentan have been shown to improve exercise capacity and time to clinical worsening.

  • Bosentan may cause reversible abnormalities in LFTs, so regular monitoring of LFTs is needed.

Phosphodiesterase-5 inhibitors

  • These drugs modulate the effects of nitric acid on vascular tone via their effect on cyclic guanosine monophosphate (cGMP) and appear to be relatively selective pulmonary arterial vasodilators. An Indian trial of sildenafil used as monotherapy in 17 patients showed some clinical improvement, but most evidence of benefit comes from trials in which this group of drugs is used in combination with endothelin-A receptor antagonists5.

  • They are traditionally used to treat erectile dysfunction. An evidence summary commissioned by the National Institute for Health and Care Excellence (NICE) suggested that whilst sildenafil may have a use in the treatment of PH in neonates in resource-limited settings where inhaled nitrous oxide is not available, there is no justification for its use in the UK10

Drugs under clinical investigation5

Other drugs under current clinical investigation include prostacyclin agonists, guanylate cyclase stimulators and calcium-channel blockers.


Pulmonary thrombo-arterectomy is sometimes considered for Group 4 patients with chronic thrombo-emboli.


Single/double-lung or cardiopulmonary transplantation may be considered in some severe cases. With pulmonary protection and immunosuppression, the long-term prognosis after lung and heart-lung transplant is good11.



  • The mean survival of people with evidence of right heart failure or severe PH (greater than 55 mm Hg mean pulmonary artery pressure) is approximately 12 months.

  • For people with preserved right heart function and a mean pulmonary artery pressure less than 55 mm Hg, survival is approximately three years.

  • Idiopathic PAH patients who are untreated are known to have a median survival of 2-3 years.

Further reading and references

  • Pulmonary Hypertension Association UK
  • PHA - Pulmonary Hypertension Association (international)
  • Gajecki D, Gawrys J, Szahidewicz-Krupska E, et al; Novel Molecular Mechanisms of Pulmonary Hypertension: A Search for Biomarkers and Novel Drug Targets-From Bench to Bed Site. Oxid Med Cell Longev. 2020 May 22;2020:7265487. doi: 10.1155/2020/7265487. eCollection 2020.
  1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension; European Society of Cardiology (Aug 2015)
  2. Kiely DG, Elliot CA, Sabroe I, et al; Pulmonary hypertension: diagnosis and management. BMJ. 2013 Apr 16;346:f2028. doi: 10.1136/bmj.f2028.
  3. Pulmonary Hypertension, Primary, 1, PPH1; Online Mendelian Inheritance in Man (OMIM)
  4. Saygin D, Domsic RT; Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment. Open Access Rheumatol. 2019 Dec 27;11:323-333. doi: 10.2147/OARRR.S228234. eCollection 2019.
  5. Pahal P et al; Secondary Pulmonary Hypertension, StatPearls Publishing, 2020.
  6. Wijeratne DT, Lajkosz K, Brogly SB, et al; Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada. Circ Cardiovasc Qual Outcomes. 2018 Feb;11(2):e003973. doi: 10.1161/CIRCOUTCOMES.117.003973.
  7. Rosenzweig EB, Barst RJ; Pulmonary arterial hypertension in children: a medical update. Indian J Pediatr. 2009 Jan;76(1):77-81. Epub 2009 Apr 18.
  8. Wang LY, Lee KT, Lin CP, et al; Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan. Acta Cardiol Sin. 2017 Sep;33(5):498-509. doi: 10.6515/acs20170612a.
  9. Barnes H, Yeoh HL, Fothergill T, et al; Prostacyclin for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2019 May 1;5:CD012785. doi: 10.1002/14651858.CD012785.pub2.
  10. Pulmonary hypertension in neonates: sildenafil; NICE Evidence summary, March 2016
  11. Toyoda Y, Thacker J, Santos R, et al; Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. Ann Thorac Surg. 2008 Oct;86(4):1116-22.
  12. Madden BP; Pulmonary hypertension and pregnancy. Int J Obstet Anesth. 2009 Apr;18(2):156-64. Epub 2009 Feb 14.

Article history

The information on this page is written and peer reviewed by qualified clinicians.

symptom checker

Feeling unwell?

Assess your symptoms online for free